Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.48 |
| ▸ | FDPS | P14324 | 3/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.48 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434099 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL9873822 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL10436118 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL9533300 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL7700878 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL10335702 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL20420634 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL10335495 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL8862993 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR | |
| SCHEMBL21799217 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935052-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | BASF SE (DE) | 2022-01-12 | — | — | EP | disclosed |
| WO-2020182587-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | BASF SE (DE) | 2020-09-17 | — | — | WO | disclosed |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7674816-B2 | Substituted melatonin derivatives, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2125694-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | Abraxis BioScience, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1701718-A4 | SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE LLC (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1976505-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | Abraxis BioScience, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008064060-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1553443-A1 | SILVER HALIDE PHOTOSENSITIVE MATERIAL AND METHOD OF FORMING IMAGE | Konica Minolta Photo Imaging, Inc. (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-6171774-B1 | YELLOW IMAGE-FORMING EMULSION LAYER CONTAINS A YELLOW DYE-FORMING COUPLER AND AN ORGANIC SOLVENT-SOLUBLE POLYMER | KONICA CORPORATION (JP) | 2001-01-09 | — | — | US | disclosed |
| US-5928850-A | WITH OXAZOLIDIONE-TYPE YELLOW COUPLER | KONICA CORPORATION (JP) | 1999-07-27 | — | — | US | disclosed |
| US-5650430-A | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO COMPANY, LIMITED (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0460950-B1 | Radicicol derivatives, their preparation and their anti-tumour activity | SANKYO CO (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0357702-A1 | FLUORINATED OLIGOPHENYL DERIVATIVES. | MERCK PATENT GMBH (DE) | 1990-03-14 | — | — | EP | disclosed |
| WO-1989006678-A1 | FLUORINATED OLIGOPHENYL DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | LCK 4583/4885PPARD 3374/4885ZDHHC20 2845/4885 |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | LCK 4583/4885PPARD 3374/4885ZDHHC20 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.